Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study

By Bajetta Emilio   Catena Laura   Fazio Nicola   Pusceddu Sara   Biondani Pamela   Blanco Giusi   Ricci Sergio   Aieta Michele   Pucci Francesca   Valente Monica   Bianco Nadia   Mauri Chiara Maria   Spada Francesca  

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2457-2463

Blackwell Publishing

Access to resources Recommend Favorite

Octreotide Long-Acting Release (LAR): A Review of its Use in the Management of Acromegaly

By Yang Lily P.H.   Keating Gillian M.  

Drugs, Vol. 70, Iss. 13, 2010-09 ,pp. : 1745-1769

Adis International

Access to resources Recommend Favorite

Octreotide Long-Acting Release (LAR): A Review of its Use in the Management of Acromegaly

By McKeage K.   Cheer S.   Wagstaff A.J.  

Drugs, Vol. 63, Iss. 22, 2003-01 ,pp. : 2473-2499

Adis International

Access to resources Recommend Favorite

Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population-based analysis

By Shen Chan   Shih Ya-Chen Tina   Xu Ying   Yao James C.  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 2039-2049

Blackwell Publishing

Access to resources Recommend Favorite

The efficacy of octreotide LAR (long acting release) treatment in patients with somatotropinoma, and mixed pituitary tumours

By Waśko Ryszard   Bolko Paweł   Owecki Maciej   Jaskuła Magdalena   Sowiński Jerzy  

Pharmacy World and Science, Vol. 26, Iss. 6, 2004-12 ,pp. : 324-327

Springer Publishing Company

Access to resources Recommend Favorite